Prestige Consumer Healthcare to Release Fiscal 2025 Second Quarter Earnings Results

PBH 10.08.2024

Full Press ReleaseSEC FilingsOur PBH Tweets

About Gravity Analytica

Recent News

  • 02.06.2025 - Q3 2025 Prestige Consumer Healthcare Inc. Earnings Conference Call
  • 01.14.2025 - ICR 2025 Conference Presentation
  • 01.09.2025 - Prestige Consumer Healthcare Announces Fiscal 2025 Third Quarter Earnings Results Date and ICR Conference Presentation

Recent Filings

  • 01.07.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.06.2025 - 8-K Current report
  • 01.06.2025 - EX-99.1 EX-99.1
PDF Version

TARRYTOWN, N.Y.,Oct. 08, 2024(GLOBE NEWSWIRE) --Prestige Consumer Healthcare Inc.(NYSE:PBH) today announced that it will issue its fiscal 2025 second quarter earnings release onThursday, November 7, 2024before the opening of the market. The Company will host a conference call to discuss the results that same morning at8:30 a.m. ET.

To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page ofwww.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the callhereto receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start.

A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat®and Summer’s Eve®women's health products, BC®and Goody's®pain relievers, Clear Eyes®and TheraTears® eye care products, DenTek®specialty oral care products, Dramamine®motion sickness treatments, Fleet®enemas and glycerin suppositories, Chloraseptic®and Luden's®sore throat treatments and drops, Compound W®wart treatments, Little Remedies®pediatric over-the-counter products, Boudreaux’s Butt Paste®diaper rash ointments, Nix®lice treatment, Debrox®earwax remover, Gaviscon®antacid in Canada, and Hydralyte®rehydration products and the Fess®line of nasal and sinus care products in Australia. Visit the Company's website atwww.prestigeconsumerhealthcare.com.

Investor Relations ContactPhil Terpolilli, CFA, 914-524-6819irinquiries@prestigebrands.com

Primary Logo

Source: Prestige Consumer Healthcare Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com